Skip to main content

New Information on the Role of Beta-Blockers in Cardiac Therapy

Cardiovascular Drugs and Therapy volume 13, pages 469–477 (1999)Cite this article

Abstract

Summary. Hypertension and ischemic heart disease are important precursors of heart failure. The prevention of progression to heart failure is a prime objective when treating patients with hypertension or ischemic heart disease. In patients with hypertension, treatment with either diuretics or beta-blockers reduces the risk of chronic heart failure. In patients with ischemic heart disease, beta-blocker therapy reduces the risk of recurrent myocardial infarction and ensuing cardiac dysfunction. The beneficial effects of beta-blocker therapy may be greater in post-infarction patients who have impaired left ventricular function than in those patients without such impairment.

When considering heart failure itself, the efficacy of angiotensin-converting enzyme (ACE) inhibitors has been demonstrated in patients with mild-to-severe left ventricular dysfunction and their use is indicated for all stages of heart failure to reduce symptoms and retard further impairment of left ventricular function. Diuretics and digitalis offer relief from the symptoms of the disease, while positive inotropes are reserved for parenteral administration in end-stage heart failure, as a bridge to transplantation, or in acute exacerbations of the disease. Added to standard therapy, beta-blockade is of value in the treatment of heart failure, preventing further deterioration and improving hemodynamics, exercise tolerance, quality of life, and long-term prognosis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. The Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 1995;92:2764–2784.

    Google Scholar 

  2. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741–751.

    Google Scholar 

  3. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;18:736–753.

    Google Scholar 

  4. Packer M, Cohn J, on behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(2A):1A–38A.

    Google Scholar 

  5. Franciosa JA. Epidemiologic patterns, clinical evaluation, and long-term prognosis in chronic congestive heart failure. Am J Med 1986;80(2B):14–21.

    Google Scholar 

  6. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:25A–30A.

    Google Scholar 

  7. Itoh A, Saito M, Haze K, Hiramori K, Kasagi F. Prognosis of patients with congestive heart failure: Its determinants in various heart diseases in Japan. Intern Med 1992;31: 304–309.

    Google Scholar 

  8. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107–115.

    Google Scholar 

  9. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214–1218.

    Google Scholar 

  10. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996;156:1789–1796.

    Google Scholar 

  11. Deedwania PC. The progression from hypertension to heart failure. Am J Hypertens 1997;10(Part 2):280S–288S.

    Google Scholar 

  12. Perera GA. Hypertensive vascular disease; description and natural history. J Chron Dis 1955;1:33–42.

    Google Scholar 

  13. Levy D, Larsson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557–1562.

    Google Scholar 

  14. Cruickshank JM, Prichard BNC. Beta-blockers in Clinical Practice. Edinburgh: Churchill Livingstone, 1988.

    Google Scholar 

  15. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38(Suppl 10);S82–S88.

    Google Scholar 

  16. Lehtonen A, Transkanen A, Temmerman J. Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients. Int J Clin Pharmacol Ther Toxicol 1987;25:448–451.

    Google Scholar 

  17. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–838.

    Google Scholar 

  18. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991;14:203–209.

    Google Scholar 

  19. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilolmetoprolol study. J Hypertens 1996;14:489–494.

    Google Scholar 

  20. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955–959.

    Google Scholar 

  21. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739–745.

    Google Scholar 

  22. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly. JAMA 1998;279:1903–1907.

    Google Scholar 

  23. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151–183.

    Google Scholar 

  24. Zanchetti A, Chalmers JP, Arakawa K, et al. The 1993 guidelines for the management of mild hypertension memorandum from a WHO/ISH meeting. Blood Press 1993;2:86–100.

    Google Scholar 

  25. Frimodt-Moeller J, Poulsen DL, Kornerup HJ, et al. Quality of life, side effects, and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. J Hum Hypertens 1991;5:215–221.

    Google Scholar 

  26. Ostergren J, Storstein L, Karlberg BE, Tibblin G. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996;5:41–49.

    Google Scholar 

  27. The Task Force of the European Society of Cardiology. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394–413.

    Google Scholar 

  28. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.

    Google Scholar 

  29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;35:1001–1009.

    Google Scholar 

  30. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.

    Google Scholar 

  31. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–371.

    Google Scholar 

  32. Hjalmarson A, Olsson G. Myocardial infarction. Effects of beta-blockade. Circulation 1991;84(Suppl VI):VI-101–VI-107.

    Google Scholar 

  33. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Fail 1997;3:249–254.

    Google Scholar 

  34. Xhignesse M, Laplante P, Grant AM, et al. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough? Can J Cardiol 1999;15:185–189.

    Google Scholar 

  35. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238–1244.

    Google Scholar 

  36. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1998;18:1569–1582.

    Google Scholar 

  37. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. Lancet 1998;339(8):489–497.

    Google Scholar 

  38. The Norwegian Multicenter Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801–807.

    Google Scholar 

  39. Herlitz J, Hjalmarson A, Waagstein F. Effect of metoprolol among patients with suspected acute myocardial infarction and left ventricular dysfunction. Eur Heart J 1996;17(Suppl):514.

    Google Scholar 

  40. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823–827.

    Google Scholar 

  41. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67(Suppl 1):I-26–I-32.

    Google Scholar 

  42. Basu S, Senior R, Raval U, van der Does R, Bruchner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96:183–191.

    Google Scholar 

  43. Kjekshus J, Swedberg K. Treatment of heart failure. J Interm Med 1996;239:335–343.

    Google Scholar 

  44. Smith TW, Kelly RA, Warner Stevenson L, Braunwald E. Management of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine Philadelphia: W.B. Saunders, 1997;492–514.

    Google Scholar 

  45. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435.

    Google Scholar 

  46. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.

    Google Scholar 

  47. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.

    Google Scholar 

  48. Kober L, Torp-Pedersen C, Carlsen JE, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670–1676.

    Google Scholar 

  49. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–677.

    Google Scholar 

  50. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685–691.

    Google Scholar 

  51. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–533.

    Google Scholar 

  52. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955–962.

    Google Scholar 

  53. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1–7.

    Google Scholar 

  54. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: Studies in normal subjects and in patients with heart disease. Ann Intern Med 1997;65:20–27.

    Google Scholar 

  55. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;7:1022–1036.

    Google Scholar 

  56. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117–133.

    Google Scholar 

  57. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134–142.

    Google Scholar 

  58. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551–563.

    Google Scholar 

  59. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374–1376.

    Google Scholar 

  60. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441–1446.

    Google Scholar 

  61. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765–1773.

    Google Scholar 

  62. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375–380.

    Google Scholar 

  63. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060–1066.

    Google Scholar 

  64. Packer M, Bristow MR, Cohn JN, et al., for the US Carvedilol Heart Failure Study. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.

    Google Scholar 

  65. Colucci WS, Packer M, Bristow MR, et al., for the US Carvedilol Heart Failure Study. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800–2806.

    Google Scholar 

  66. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807–2816.

    Google Scholar 

  67. Packer M, Colucci WS, Sackner-Bernstein JD, et al., for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure The PRECISE Trial. Circulation 1996;94:2793–2799.

    Google Scholar 

  68. Cohn JN, Fowler MB, Bristow MR, et al., for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure J Cardiac Failure 1997;3:173–179.

    Google Scholar 

  69. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure. Circulation 1998;98:1184–1191.

    Google Scholar 

  70. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9–13.

    Google Scholar 

  71. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999;353:2001–2007

    Google Scholar 

  72. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta blocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trials. Eur Heart J 1997;8:560–565.

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of Heart and Lung Diseases Göteborg University and Department of Clinical Pharmacology, Sahlgrenska University Hospital, Göteborg, Sweden

    Anders Himmelmann

Authors
  1. Anders Himmelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Himmelmann, A. New Information on the Role of Beta-Blockers in Cardiac Therapy. Cardiovasc Drugs Ther 13, 469–477 (1999). https://doi.org/10.1023/A:1007893301243

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007893301243

  • angina pectoris
  • beta-blockers
  • heart failure
  • hypertension
  • ischemic heart disease